A phase I clinical trial of ursolic acid nanoliposome for evaluating its single-dose tolerance and safety

Chinese Journal of New Drugs

Volumn 20, Issue 2, 2011, Pages 148-151

  Zhao, Cui Cui ^a   Qian, Zheng Zi ^a   Wang, Hua Qing ^a   Song, Zheng ^a   Meng, Xiang Rui ^a   Zhao, Jing ^a   Yan, Zhao ^a   Hao, Xi Shan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Nanoliposome; Phase I clinical trial; Tolerance; Ursolic acid

Indexed keywords

URSOLIC ACID DERIVATIVE;

ABDOMINAL DISTENSION; ARTICLE; DIARRHEA; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; HEMATURIA; HUMAN; LIVER TOXICITY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHYSICAL CHEMISTRY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SODIUM BLOOD LEVEL; VITAL SIGN;

EID: 79953053705     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. TIAN Z, LIN G, ZHENG RX, et al. Anti-hepatoma activity and mechanism of ursolic acid and its derivatives isolated from Aralia decaisneana[J]. World J Gastroenterol, 2006,12(6):874-879.
2. YAN SL, HUANG CY, WU ST, et al. Oleanolic acid and ursolic acid induce apoptosis in four human liver cancer cell lines[J]. Toxicol in Vitro, 2010,24(3):842-848.
3. DAS B, YEGER H, TSUCHIDA R, et al. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1 alpha through mitogen activated protein kinase/extracellularsignal-regulated kinase1/2 pathway in neuroblastoma[J]. Cancer Res, 2005,65(16):7267-7275.